Ripretinib
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) [1][2]. DCC-2618 exerts antineoplastic effect and induces apoptosis[3].
Product Specifications
CAS Number
1442472-39-0
Product Name Alternative
DCC-2618
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Apoptosis; c-Kit; FLT3; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/DCC-2618.html
Purity
98.90
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(C2=CC3=C(C=C(NC)N=C3)N(CC)C2=O)=C(Br)C=C1F)NC4=CC=CC=C4
Molecular Formula
C24H21BrFN5O2
Molecular Weight
510.36
Precautions
H315, H319, H320
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDGFRα
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SREBP2 (SREBP2/1579), CF640R conjugate, 0.1mg/mL
